TDC
ACER

Thompson Davis & Co’s Acer Therapeutics Inc ACER Stock Holding History

Thompson Davis & Co’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$42K Buy
+1,365
New +$36.6K 0.09% 227
2016
Q2 		– Sell
-38
Closed -$1K – 1202
2016
Q1 		$1K Hold
38
– – ﹤0.01% 1049
2015
Q4 		$1K Buy
+38
New +$1.26K ﹤0.01% 1105

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Thompson Davis & Co's ACER Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in Acer Therapeutics Inc (ACER) in Q3 2018: 1,365 shares worth $42K. The stake represents 0.09% of the portfolio and ranks #227 among its holdings. This is a return to the name: Thompson Davis & Co previously reported a position in ACER as recently as Q1 2016.

Thompson Davis & Co first reported a position in ACER in Q4 2015 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold ACER as of Q3 2018.

  • Thompson Davis & Co held 1,365 shares of Acer Therapeutics Inc worth $42K as of Q3 2018.
  • Acer Therapeutics Inc was a new Thompson Davis & Co position in Q3 2018.
  • Acer Therapeutics Inc made up 0.09% of Thompson Davis & Co's portfolio in Q3 2018, its #227 holding.
  • Thompson Davis & Co first reported a position in Acer Therapeutics Inc in Q4 2015 and has held it in 3 quarters since.
  • 29 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.